[Phase II study of etoposide (VP-16) in the form of oral capsules for malignant lymphomas].

Abstract

Twenty-five patients with malignant lymphomas were treated with etoposide oral capsule 200mg/day for 5 days, repeated 3-4-weekly. Twenty-one cases were evaluable. CR was achieved in four cases (19.0%) and PR in six cases (28.6%). The most serious adverse effect of the drug was leukopenia. In one patient (6.7%) the leukocyte count was lower than 1,000/mm3. Gastrointestinal toxicities such as anorexia, nausea, vomiting and diarrhea occurred in about 66.7% of patients but were not serious; alopecia was observed in 65.2%. In conclusion, etoposide is considered effective for malignant lymphomas.

• Authors: I Konishi, T Kitani, K Nagai, A Kanamaru, M Kohsaki, T Masaoka, H Shibata, A Horiuchi, K Tsubaki, H Kawagoe
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 12 Issue 7 Pg. 1482-6 (Jul 1985) ISSN: 0385-0684 [Print] Japan
• PMID: 4015122 (Publication Type: English Abstract, Journal Article)

Chemical References

• Capsules
• Etoposide
• Podophyllotoxin

Topics

• Administration, Oral
• Adult
• Aged
• Capsules
• Drug Administration Schedule
• Drug Evaluation
• Etoposide (administration & dosage, adverse effects)
• Female
• Humans
• Leukopenia (chemically induced)
• Lymphoma (drug therapy)
• Male
• Middle Aged
• Podophyllotoxin (analogs & derivatives)
• Thrombocytopenia (chemically induced)